Zomedica Corp (ZOM)

[Ruben3009]

Guys, this is unstoppable!!! No matter how much the hedge fund and market makers want to short this stock, no matter how much they squeeze, Trueforma will sell, and the stock will go up. Be patient, don’t sell.


The last time I weighed in on Zomedica (NYSEAMERICAN:ZOM), I said, “While there are plenty of reasons to be bullish on [ZOM Stock] for the long run, there is also reason for near-term caution.”


Persian cat with veterinarian doctor at vet clinic
Source: didesign021 / Shutterstock.com
That was on Feb. 24, as ZOM stock traded at a high of $2.19. It’s now at $1.58.

Around that time the company, which makes point-of-care diagnostic products for cats and dogs, had just rallied about 2,900% on two key catalysts.

One, the pet care industry was howling.

“Pet owners are spending billions on premium-quality foods, state-of-the-art health care, insurance policies, luxury services and more. It’s causing a new pet care economy to emerge that could reach $203 billion by 2025,” noted Michael L. Sapir, CEO of ProShare Advisors LLC in a company press release.

Two, the company was nearing the commercialization of its Transforma diagnostic tool. Even after all of that, I believe the stock could double if its product performs well with veterinarians.

The Animal Diagnostics Market Could be Worth up to $5.38 Billion